Roche licenses new flu-fighting technology
Washington, February 9, 2010
Roche AG's Genentech unit has licensed an experimental new technology that uses antibodies to fight influenza, including H1N1 swine flu, Harvard's Dana Farber Cancer Institute said.
Dana-Farber said it and the Sanford-Burnham Medical Research Institute had signed a license agreement with Genentech, giving the company exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses.
Dr Wayne Marasco at Dana-Farber, Robert Liddington at Sanford-Burnham and Ruben Donis of the the Centers for Disease Control and Prevention discovered the antibody technology and reported on it a year ago this month.
The antibodies -- immune system proteins that attach to invaders such as viruses -- can be used as direct treatment for flu. They also might be used to protect front-line workers and others at high risk during pandemics.
In studies, the antibodies -- generated from the blood of 57 volunteers -- neutralised a wide range of influenza viruses.
Influenza viruses cloak themselves in lollipop-shaped proteins called hemagglutinin and neuraminidase, which mutate regularly and give influenza A strains the "H" and "N" designations in their names.
Vaccines target hemagglutinin, while drugs called neuraminidase inhibitors, including Roche's Tamiflu and GlaxoSmithKline's Relenza, attack neuraminidase.
Because of virus mutations, vaccines have to be reformulated every year, and the viruses can develop resistance to the neuraminidase inhibitors, as they have to older antivirals.
The antibodies attach to a less mutation-prone part of the virus, on the "stick" part of the lollipop, the researchers said.
The researchers used the natural antibodies as the basis for lab-engineered versions, called human monoclonal antibodies.
Marasco has said it should be straightforward to develop the antibodies as drugs, because they are already used broadly in cancer therapy.
Cancer monoclonal antibodies can cost tens of thousands of dollars a year, but Marasco said companies have learned how to make them more cheaply recently. -Reuters
More Health & Environment Stories
- Dubai Healthcare City inks deal with UAE universities
- University of Ain Shams opens MS treatment unit
- Bahrain's humidity could ease water crisis
- Visibility in Bahrain forecast to improve
- Bahrain-India venture plans hospitals in GCC
- Seha launches new health initiative
- Veolia backs Oman waste management meet
- Obesity rate at 72pc among Saudi adults
- Bahrain ideal for artificial rain experiment
- Riyadh 'among most polluted cities'
- CGM acquires 3 European healthcare IT providers
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman